

# Targeted treatment in HER2–breast cancer: from eBC to aBC

Thursday 11 June 2026 | 10:30–11:30 | Hall D

This promotional meeting is organised and funded by AstraZeneca and is intended for healthcare professionals in the UK only. Prescribing Information (PI) and adverse event reporting statements can be accessed by scanning or clicking the QR codes at the bottom of this flyer.

Join us for our UK Oncology Forum (UKOF) 2026 symposium where our panel of specialists aim to cover:



Understanding the updated *BRCA* testing eligibility criteria and their use in clinical practice



Assessing the clinical relevance of *PIK3CA/ACT1/PTEN* and *ESR1* co-mutation data, and how these findings may influence patient selection and management



Evaluating concordance between tissue and ctDNA-based testing, and the potential clinical implications



Identifying gaps and opportunities through audit data to optimise testing pathways and treatment implementation



**Dr Marina Parton (Chair)**  
Consultant Medical Oncologist,  
The Royal Marsden NHS  
Foundation Trust



**Suzanne Frank**  
Advanced Specialist Breast  
Cancer Pharmacist, The Christie  
NHS Foundation Trust



**Dr Ciara O'Brien**  
Consultant & Honorary Senior  
Lecturer in Medical Oncology,  
The Christie NHS Foundation Trust

Time (BST)	Presentation	Speaker(s)
10:30–10:35	Welcome and introduction	Dr Marina Parton
10:35–11:00	Evidence to eligibility: practical implications of <i>BRCA</i> testing updates	Suzanne Frank
11:00–11:10	Co-occurring mutations in HER2–breast cancer: what the data show	Dr Ciara O'Brien
11:10–11:20	Insights on capivasertib from the clinic: an RMH audit	Dr Marina Parton
11:20–11:30	Panel discussion with Q&A and closing summary	All, facilitated by Dr Marina Parton

Scan or click the QR codes to access the relevant PI and adverse event reporting statements



LYNPARZA® (PI)



TRUQAP® (PI)



Fulvestrant (PI)

aBC, advanced breast cancer; *AKT1*, serine/threonine kinase; *BRCA*, breast cancer gene; BST, British Summer Time; ctDNA, circulating tumour DNA; eBC, early breast cancer; *ESR1*, oestrogen receptor 1; HER2–, human epidermal growth factor receptor 2 negative; NHS, National Health Service; PI, Prescribing Information; *PIK3CA*, phosphatidylinositol 3-kinase catalytic subunit alpha; *PTEN*, phosphatase and tensin homologue; RMH, Royal Marsden Hospital.

LYNPARZA and TRUQAP are registered trademarks of the AstraZeneca group of companies.

© AstraZeneca 2026. All rights reserved.

GB-76246 | May 2026